54573-75-0,MFCD00871065
Catalog No.:AA00DA8X

54573-75-0 | Doxercalciferol

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$23.00   $16.00
- +
2mg
98%
in stock  
$33.00   $23.00
- +
5mg
98%
in stock  
$59.00   $42.00
- +
10mg
98%
in stock  
$82.00   $57.00
- +
25mg
98%
in stock  
$137.00   $96.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00DA8X
Chemical Name:
Doxercalciferol
CAS Number:
54573-75-0
Molecular Formula:
C28H44O2
Molecular Weight:
412.6478
MDL Number:
MFCD00871065
SMILES:
O[C@H]1C[C@H](O)C(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](/C=C/[C@@H](C(C)C)C)C)C)/C1
Properties
Properties
 
Form:
Solid  
MP:
>145°C  
Storage:
Keep in dry area;-20 ℃;  

Computed Properties
 
Complexity:
712  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
7  
Defined Bond Stereocenter Count:
3  
Formal Charge:
0  
Heavy Atom Count:
30  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0  
Rotatable Bond Count:
5  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
6.3  

Downstream Synthesis Route

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

Literature

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.

Journal: Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20120101

Title: Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats.

Journal: Journal of cardiac failure 20111201

Title: Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor.

Journal: Journal of molecular endocrinology 20110401

Title: Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism.

Journal: American journal of physiology. Renal physiology 20110301

Title: Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.

Journal: Kidney international 20110101

Title: Comparative effectiveness of active oral vitamin D agents in patients on peritoneal dialysis.

Journal: Nephrology news & issues 20110101

Title: Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.

Journal: The American journal of pathology 20100801

Title: Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.

Journal: Kidney international. Supplement 20100801

Title: Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.

Journal: Kidney international. Supplement 20100801

Title: A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.

Journal: Clinical journal of the American Society of Nephrology : CJASN 20100201

Title: Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.

Journal: Blood purification 20100101

Title: A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol.

Journal: Molecules (Basel, Switzerland) 20090929

Title: Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.

Journal: American journal of physiology. Renal physiology 20090901

Title: Vitamin D receptor activators.

Journal: The International journal of artificial organs 20090201

Title: Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.

Journal: American journal of nephrology 20090101

Title: Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20081201

Title: Vitamin D receptor ligand therapy in chronic kidney disease.

Journal: Clinical nephrology 20081001

Title: Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study.

Journal: Clinical nephrology 20081001

Title: Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20080415

Title: Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.

Journal: Leukemia & lymphoma 20080101

Title: Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20080101

Title: Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.

Journal: Nephrology nursing journal : journal of the American Nephrology Nurses' Association 20080101

Title: 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma.

Journal: Journal of neuro-oncology 20071201

Title: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.

Journal: Kidney international 20070901

Title: [Treatment of hypoparathyroidism by active vitamin D].

Journal: Clinical calcium 20070801

Title: Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.

Journal: Journal of managed care pharmacy : JMCP 20070601

Title: [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].

Journal: Clinical calcium 20070501

Title: Survival differences between activated injectable vitamin D2 and D3 analogs.

Journal: Kidney international 20070401

Title: Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Journal: Drugs 20070101

Title: Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.

Journal: Drugs 20070101

Title: Functional evolution of the vitamin D and pregnane X receptors.

Journal: BMC evolutionary biology 20070101

Title: Mortality risk among hemodialysis patients receiving different vitamin D analogs.

Journal: Kidney international 20061101

Title: Doxercalciferol treatment of secondary hyperparathyroidism.

Journal: The Annals of pharmacotherapy 20061101

Title: Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.

Journal: Clinical nephrology 20060501

Title: The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060301

Title: Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.

Journal: Clinical journal of the American Society of Nephrology : CJASN 20060301

Title: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2.

Journal: Biochimica et biophysica acta 20060201

Title: Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.

Journal: Journal of the American Society of Nephrology : JASN 20050801

Title: Are new vitamin D analogues in renal bone disease superior to calcitriol?

Journal: Pediatric nephrology (Berlin, Germany) 20050301

Title: Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.

Journal: American journal of nephrology 20050101

Title: Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug.

Journal: Anticancer research 20050101

Title: 1 Alpha-hydroxyvitamin D2 and 1 alpha-hydroxyvitamin D3 have anabolic effects on cortical bone, but induce intracortical remodeling at toxic doses in ovariectomized rats.

Journal: Bone 20040901

Title: Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models.

Journal: Archives of ophthalmology (Chicago, Ill. : 1960) 20040901

Title: Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model.

Journal: Archives of ophthalmology (Chicago, Ill. : 1960) 20040901

Title: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation 20040501

Title: [The trend in the development of the active vitamin D3 and its analogues].

Journal: Nihon rinsho. Japanese journal of clinical medicine 20040501

Title: CYP3A4 is a human microsomal vitamin D 25-hydroxylase.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040401

Title: Calcimimetics versus vitamin D: what are their relative roles?

Journal: Blood purification 20040101

Title: Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20030915

Title: Prevention and treatment of secondary hyperparathyroidism: still a challenge for the nephrologist?

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030701

Title: Effect of doxercalciferol (1alpha-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy.

Journal: Clinical nephrology 20030601

Title: A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients.

Journal: Clinical nephrology 20030501

Title: Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030401

Title: Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice.

Journal: Ophthalmology 20030401

Title: Synthesis of C-19-functionalized 1alpha-hydroxyvitamin D(2) analogues via ring-closing metathesis.

Journal: Organic letters 20030306

Title: [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].

Journal: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20030101

Title: Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats.

Journal: Kidney international 20021001

Title: Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20020901

Title: Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient.

Journal: Clinical nephrology 20020801

Title: Use of vitamin D(4) analogs to investigate differences in hepatic and target cell metabolism of vitamins D(2) and D(3).

Journal: Biochimica et biophysica acta 20020711

Title: Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model.

Journal: Archives of ophthalmology (Chicago, Ill. : 1960) 20020501

Title: Vitamin D analogs for the treatment of secondary hyperparathyroidism.

Journal: Blood purification 20020101

Title: Comparative review of the pharmacokinetics of vitamin D analogues.

Journal: Seminars in dialysis 20020101

Title: Vitamin D analogues for secondary hyperparathyroidism.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020101

Title: Toxicity and dose-response studies of 1 alpha-hydroxyvitamin D2 in LH beta-Tag transgenic mice.

Journal: Transactions of the American Ophthalmological Society 20020101

Title: Vitamin D analogues for the management of secondary hyperparathyroidism.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation 20011101

Title: 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20010401

Title: Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation 20010301

Title: New vitamin D analogs.

Journal: Seminars in dialysis 20010101

Title: Noonan W, et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant. 2008 Dec;23(12):3824-30.

Title: Wang XX, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011 Mar;300(3):F801-10.

Title: Wang Y, et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012 Dec;23(12):1977-86.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:54573-75-0 Molecular Formula|54573-75-0 MDL|54573-75-0 SMILES|54573-75-0 Doxercalciferol
Catalog No.: AA00DA8X
54573-75-0,MFCD00871065
54573-75-0 | Doxercalciferol
Pack Size: 1mg
Purity: 98%
in stock
$23.00 $16.00
Pack Size: 2mg
Purity: 98%
in stock
$33.00 $23.00
Pack Size: 5mg
Purity: 98%
in stock
$59.00 $42.00
Pack Size: 10mg
Purity: 98%
in stock
$82.00 $57.00
Pack Size: 25mg
Purity: 98%
in stock
$137.00 $96.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00DA8X
Chemical Name: Doxercalciferol
CAS Number: 54573-75-0
Molecular Formula: C28H44O2
Molecular Weight: 412.6478
MDL Number: MFCD00871065
SMILES: O[C@H]1C[C@H](O)C(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](/C=C/[C@@H](C(C)C)C)C)C)/C1
Properties
Form: Solid  
MP: >145°C  
Storage: Keep in dry area;-20 ℃;  
Complexity: 712  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 7  
Defined Bond Stereocenter Count: 3  
Formal Charge: 0  
Heavy Atom Count: 30  
Hydrogen Bond Acceptor Count: 2  
Hydrogen Bond Donor Count: 2  
Isotope Atom Count: 0  
Rotatable Bond Count: 5  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 6.3  
Downstream Synthesis Route
73809-45-7    54573-75-0 

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

74035-72-6    54573-75-0 

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

67657-85-6    54573-75-0 

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

72204-99-0    54573-75-0 

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

50-14-6    54573-75-0 

[1]Paaren,HerbertE.;DeLuca,HectorF.;Schnoes,HeinrichK.[JournalofOrganicChemistry,1980,vol.45,#16,p.3253-3258]

Literature fold

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters20130801

Title: Converting to doxercalciferol capsules from intravenous paricalcitol or doxercalciferol.

Journal: Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation20120101

Title: Doxercalciferol, a pro-hormone of vitamin D, prevents the development of cardiac hypertrophy in rats.

Journal: Journal of cardiac failure20111201

Title: Direct suppression of Pth gene expression by the vitamin D prohormones doxercalciferol and calcidiol requires the vitamin D receptor.

Journal: Journal of molecular endocrinology20110401

Title: Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism.

Journal: American journal of physiology. Renal physiology20110301

Title: Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.

Journal: Kidney international20110101

Title: Comparative effectiveness of active oral vitamin D agents in patients on peritoneal dialysis.

Journal: Nephrology news & issues20110101

Title: Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats.

Journal: The American journal of pathology20100801

Title: Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.

Journal: Kidney international. Supplement20100801

Title: Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.

Journal: Kidney international. Supplement20100801

Title: A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease.

Journal: Clinical journal of the American Society of Nephrology : CJASN20100201

Title: Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.

Journal: Blood purification20100101

Title: A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol.

Journal: Molecules (Basel, Switzerland)20090929

Title: Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist.

Journal: American journal of physiology. Renal physiology20090901

Title: Vitamin D receptor activators.

Journal: The International journal of artificial organs20090201

Title: Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.

Journal: American journal of nephrology20090101

Title: Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association20081201

Title: Vitamin D receptor ligand therapy in chronic kidney disease.

Journal: Clinical nephrology20081001

Title: Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study.

Journal: Clinical nephrology20081001

Title: Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20080415

Title: Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.

Journal: Leukemia & lymphoma20080101

Title: Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists20080101

Title: Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.

Journal: Nephrology nursing journal : journal of the American Nephrology Nurses' Association20080101

Title: 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma.

Journal: Journal of neuro-oncology20071201

Title: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.

Journal: Kidney international20070901

Title: [Treatment of hypoparathyroidism by active vitamin D].

Journal: Clinical calcium20070801

Title: Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.

Journal: Journal of managed care pharmacy : JMCP20070601

Title: [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].

Journal: Clinical calcium20070501

Title: Survival differences between activated injectable vitamin D2 and D3 analogs.

Journal: Kidney international20070401

Title: Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Journal: Drugs20070101

Title: Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease.

Journal: Drugs20070101

Title: Functional evolution of the vitamin D and pregnane X receptors.

Journal: BMC evolutionary biology20070101

Title: Mortality risk among hemodialysis patients receiving different vitamin D analogs.

Journal: Kidney international20061101

Title: Doxercalciferol treatment of secondary hyperparathyroidism.

Journal: The Annals of pharmacotherapy20061101

Title: Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.

Journal: Clinical nephrology20060501

Title: The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association20060301

Title: Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.

Journal: Clinical journal of the American Society of Nephrology : CJASN20060301

Title: Evidence for the activation of 1alpha-hydroxyvitamin D2 by 25-hydroxyvitamin D-24-hydroxylase: delineation of pathways involving 1alpha,24-dihydroxyvitamin D2 and 1alpha,25-dihydroxyvitamin D2.

Journal: Biochimica et biophysica acta20060201

Title: Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.

Journal: Journal of the American Society of Nephrology : JASN20050801

Title: Are new vitamin D analogues in renal bone disease superior to calcitriol?

Journal: Pediatric nephrology (Berlin, Germany)20050301

Title: Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol.

Journal: American journal of nephrology20050101

Title: Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug.

Journal: Anticancer research20050101

Title: 1 Alpha-hydroxyvitamin D2 and 1 alpha-hydroxyvitamin D3 have anabolic effects on cortical bone, but induce intracortical remodeling at toxic doses in ovariectomized rats.

Journal: Bone20040901

Title: Effectiveness of vitamin D analogues in treating large tumors and during prolonged use in murine retinoblastoma models.

Journal: Archives of ophthalmology (Chicago, Ill. : 1960)20040901

Title: Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model.

Journal: Archives of ophthalmology (Chicago, Ill. : 1960)20040901

Title: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation20040501

Title: [The trend in the development of the active vitamin D3 and its analogues].

Journal: Nihon rinsho. Japanese journal of clinical medicine20040501

Title: CYP3A4 is a human microsomal vitamin D 25-hydroxylase.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research20040401

Title: Calcimimetics versus vitamin D: what are their relative roles?

Journal: Blood purification20040101

Title: Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20030915

Title: Prevention and treatment of secondary hyperparathyroidism: still a challenge for the nephrologist?

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association20030701

Title: Effect of doxercalciferol (1alpha-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy.

Journal: Clinical nephrology20030601

Title: A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients.

Journal: Clinical nephrology20030501

Title: Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association20030401

Title: Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice.

Journal: Ophthalmology20030401

Title: Synthesis of C-19-functionalized 1alpha-hydroxyvitamin D(2) analogues via ring-closing metathesis.

Journal: Organic letters20030306

Title: [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].

Journal: Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia20030101

Title: Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats.

Journal: Kidney international20021001

Title: Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20020901

Title: Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient.

Journal: Clinical nephrology20020801

Title: Use of vitamin D(4) analogs to investigate differences in hepatic and target cell metabolism of vitamins D(2) and D(3).

Journal: Biochimica et biophysica acta20020711

Title: Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model.

Journal: Archives of ophthalmology (Chicago, Ill. : 1960)20020501

Title: Vitamin D analogs for the treatment of secondary hyperparathyroidism.

Journal: Blood purification20020101

Title: Comparative review of the pharmacokinetics of vitamin D analogues.

Journal: Seminars in dialysis20020101

Title: Vitamin D analogues for secondary hyperparathyroidism.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association20020101

Title: Toxicity and dose-response studies of 1 alpha-hydroxyvitamin D2 in LH beta-Tag transgenic mice.

Journal: Transactions of the American Ophthalmological Society20020101

Title: Vitamin D analogues for the management of secondary hyperparathyroidism.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation20011101

Title: 1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research20010401

Title: Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation20010301

Title: New vitamin D analogs.

Journal: Seminars in dialysis20010101

Title: Noonan W, et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant. 2008 Dec;23(12):3824-30.

Title: Wang XX, et al. Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism. Am J Physiol Renal Physiol. 2011 Mar;300(3):F801-10.

Title: Wang Y, et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol. 2012 Dec;23(12):1977-86.

Building Blocks More >
53059-28-2
53059-28-2
3-(4-Methoxyphenyl)aniline
AA00DAC2 | MFCD03424668
56209-31-5
56209-31-5
5-HYDROXYINDOLE-3-ACETIC-2,2-D2 ACID
AA00DAIW | MFCD01073943
448250-78-0
448250-78-0
4-[(2-isopropylphenyl)amino]-4-oxobutanoic acid
AA00DAOU | MFCD01034361
43071-47-2
43071-47-2
2-(4-Chlorophenyl)-3-methylquinoline-4-carboxylic acid
AA00DASQ | MFCD01114916
451492-95-8
451492-95-8
Av-412
AA00DB25 | MFCD16038939
496807-64-8
496807-64-8
EN460
AA00DB5Q | MFCD02951227
4651-72-3
4651-72-3
(2-Amino-4,5,6,7-tetrahydro-benzo[b]thiophen-3-yl)-phenyl-methanone
AA00DBAY | MFCD00450864
537017-56-4
537017-56-4
2-((5-(4-Chlorophenyl)-4-(furan-2-ylmethyl)-4H-1,2,4-triazol-3-yl)thio)acetic acid
AA00DBFR | MFCD08444445
521-52-8
521-52-8
Vulpinic acid
AA00DBMH | MFCD00075804
54640-02-7
54640-02-7
Methyl 4-(aminomethyl)cyclohexanecarboxylate hydrochloride
AA00DBT0 | MFCD03093748
Submit
© 2017 AA BLOCKS, INC. All rights reserved.